PRESS RELEASE published on 06/24/2025 at 20:00, 10 months 7 days ago Inside Information / Other news releases MaaT Pharma presents Annual General Meeting results, with shareholders approving most resolutions. Jean-Marie Lefevre appointed Chairman. Liquidity contract with Kepler Cheuvreux maintained Annual General Meeting Shareholders Liquidity Contract MaaT Pharma Jean-Marie Lefevre
BRIEF published on 06/19/2025 at 19:05, 10 months 12 days ago MaaT Pharma Advances Xervyteg® Commercialization Efforts European Market Clinical Trials Oncology Microbiome Xervyteg®
PRESS RELEASE published on 06/19/2025 at 19:00, 10 months 12 days ago Inside Information / Other news releases MaaT Pharma provides business update & highlights key milestones for 2025, including MA application submission for Xervyteg, strategic focus in Europe & US trial launch Business Update Clinical-stage Biotechnology MaaT Pharma Key Milestones Xervyteg
BRIEF published on 06/13/2025 at 07:35, 10 months 18 days ago MaaT Pharma Reveals Promising Data for Xervyteg® at EHA Congress Clinical Efficacy Safety Profile Xervyteg® AGvHD EMA Application
PRESS RELEASE published on 06/13/2025 at 07:30, 10 months 18 days ago Inside Information / Other news releases MaaT Pharma presents updated positive data for Xervyteg® in treating acute Graft-versus-Host Disease at EHA Congress, validating high efficacy observed in pivotal ARES study MaaT Pharma Acute Graft-versus-Host Disease EMA Approval Xervyteg EAP Data
BRIEF published on 05/12/2025 at 07:35, 11 months 20 days ago Promising data for MaaT033 in ALS Microbiome Amyotrophic Lateral Sclerosis MaaT033 Safety And Tolerability Phase 1b Clinical Trial
BRIEF published on 04/08/2025 at 07:35, 1 year ago MaaT Pharma Announces Positive Interim Safety Results for MaaT033 Phase 2B Trial MaaT Pharma MaaT033 Allo-HSCT DSM Safety
PRESS RELEASE published on 04/08/2025 at 07:30, 1 year ago Inside Information / Other news releases MaaT Pharma announces positive safety interim analysis from DSMB for Phase 2b trial evaluating MaaT033 for patients receiving Allo-HSCT, demonstrating favorable safety profile and tolerability Phase 2B Trial MaaT Pharma Safety Analysis MaaT033 Allo-HSCT
BRIEF published on 04/07/2025 at 07:35, 1 year ago MaaT Pharma: New cover by HC Wainwright & Co Cancer Euronext Listing Microbiome Ecosystem Therapies MaaT Pharma HC Wainwright & Co
BRIEF published on 03/27/2025 at 07:35, 1 year 1 month ago MaaT Pharma announces a capital increase of 13 million euros and 2024 annual results Financial Results Biotechnology Capital Increase MaaT013 AGvH
Published on 05/02/2026 at 00:50, 39 minutes ago CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/02/2026 at 00:00, 1 hour 29 minutes ago Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 1 hour 29 minutes ago Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Published on 05/01/2026 at 22:30, 2 hours 59 minutes ago Nextech3D.ai Appoints New Independent Auditor
Published on 05/01/2026 at 22:30, 2 hours 59 minutes ago Integrated Rewards Achieves SOC 2 Compliance to Support Enterprise-Scale Growth Across Canada's Card-Linked Rewards Network as EQ Closes Convertible Debt Financing
Published on 05/01/2026 at 19:23, 6 hours 6 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 17:45, 7 hours 43 minutes ago Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 8 hours 7 minutes ago Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares
Published on 04/30/2026 at 20:00, 1 day 5 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 1 day 6 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 day 6 hours ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day 7 hours ago Minutes of the Combined General Meeting held on April 30, 2026
